Evidence map›Paper›PMID 41932337›Full record

ArticleStem cell reports2026

Rheostats, not switches: Nuclear receptor dosage tunes somatic-to-iPSC reprogramming.

Constantinos Chronis

Abstract readComment
In one paragraph

Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Constantinos ChronisDepartment of Biochemistry and Molecular Genetics, University of Illinois Chicago, MBRB 2370, 900 S Ashland Av, Chicago, IL 60607, USA. Electronic address: chronis@uic.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear receptors are modular transcription factors regulated by ligands, chromatin context, and expression level. Wang et al. 2026, in this issue of Stem Cell Reports show that Rora controls OKS-mediated reprogramming in a dose-dependent manner: moderate expression enhances iPSC formation, while high levels inhibit it, linking quantitative Rora control to immune and WNT signaling during cell fate conversion.

Indexed as

Cellular ReprogrammingInduced Pluripotent Stem CellsReceptors, Cytoplasmic and NuclearAnimalsCell DifferentiationHumansReceptors, Cytoplasmic and Nuclear

Identifiers

PMID41932337
PMCPMC13083785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.